Sage Group plc Unsponsored ADR (SGPYY)
OTC PINK OTC PINK Primary 
The Schall Law Firm Is Investigating Sage Therapeutics Inc. For Potential Securities Violations And Encourages Investors Who Have Incurred Losses To Engage In Discussions
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Investigating Sage Therapeutics Inc. For Potential Securities Violations And Urges Investors Who Have Incurred Losses To Initiate Discussions
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Investigating Sage Therapeutics Inc. For Potential Securities Violations And Encourages Investors Who Have Incurred Losses To Initiate Discussions
LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Sage Therapeutics Inc Is Under The Schall Law Firm's Probe For Possible Securities Breaches And Investors With Losses Are Encouraged To Begin Conversations
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sage Therapeutics Inc Is Being Investigated By The Schall Law Firm For Potential Securities Violations And Investors With Losses Are Urged To Initiate Dialogue
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sage Therapeutics Inc Is Under Investigation By The Schall Law Firm For Potential Securities Violations, And Investors With Losses Are Encouraged To Initiate Dialogue
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Sage Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Investors With Losses Urged To Engage In Dialogue
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Sage Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Investors With Losses Urged To Engage In Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Sage Group shares slip as revenue growth slows
The Sage Group PLC (LSE:SGE) shares plummeted close to 5% despite it reporting third-quarter results in line with expectations and keeping its guidance unchanged. Analysts at Shore Capital labelled the results “a reassuring trading update” and said it expected a “neutral/slightly positive reaction in the shares this morning”.
